Kengreal cangrelor regulatory update

FDA approved an NDA from The Medicines Co. for Kengreal cangrelor as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural thrombotic events, repeat coronary revascularization and stent thrombosis. The reversible purinergic receptor P2Y G protein-coupled 12 ( P2RY12; P2Y12) antagonist is indicated in patient s who have not been treated with a P2Y12 platelet inhibitor and are not being given an integrin alpha(2b)beta(3) ( GPIIb/IIIa; CD41/CD61) inhibitor. The company plans to launch the drug this month but declined to disclose pricing. ...